Acetylon Pharmaceuticals, Inc. (Acetylon)

Oncology Corporate Profile

HQ Location

70 Fargo Street, Suite 205
Boston, MA 2210

Company Description

Acetylon Pharmaceuticals, Inc., based in Boston, Massachusetts, is a leader in the development of novel small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The Company's epigenetic drug discovery platform has yielded a proprietary portfolio of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation through selective HDAC inhibition is thought to be applicable to a broad range of diseases including cancer, sickle cell disease and beta-thalassemia, and autoimmune and neurodegenerative diseases. Acetylon's lead drug candidate, ricolinostat (ACY-1215), is a selective HDAC6 inhibitor currently in Phase 1b clinical development for the treatment of multiple myeloma.

Website: Http://

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Acy-1215histone deacetylase (HDAC) inhibitorMultiple MyelomaIICelgene
Acy-1215 + pomalidomide)histone deacetylase (HDAC) inhibitorMultiple MyelomaIICelgene
Acy-1215 (+ lenalidomide and dexamethasone)histone deacetylase (HDAC) inhibitorMultiple MyelomaICelgene
Acy-1215 (+ bortezomib and dexamethasone)histone deacetylase (HDAC) inhibitorMultiple MyelomaICelgene

Source: http://www.acetylon

Recent News Headlines

There are no news items to display